Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
Merck
Medtronic
Baxter

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR NESACAINE-MPF


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Nesacaine-mpf

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00845962 ↗ A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia Completed Centre hospitalier de l'Université de Montréal (CHUM) N/A 2009-02-01 The purpose of this study is to compare the efficacity and the readiness for discharge between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia.
NCT00845962 ↗ A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia Completed Université de Montréal N/A 2009-02-01 The purpose of this study is to compare the efficacity and the readiness for discharge between two local anesthetics, bupivacaine and 2-chloroprocaine, used for spinal anesthesia.
NCT02862912 ↗ Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal) Completed Columbia University Phase 4 2016-11-08 This study aims to determine whether or not spinal anesthesia with the local anesthetic drug, chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in faster discharge from the post-anesthesia care unit after surgery.
NCT03260972 ↗ Intraabdominal Chloroprocaine During Cesarean Delivery for Pain Control Withdrawn Johns Hopkins University Phase 3 2021-06-01 Objective The objective of this study is to test the hypothesis that instillation of intra-abdominal chloroprocaine during cesarean deliveries is associated with decreased postoperative pain and nausea compared to placebo, without increasing intraoperative and postoperative complications. Methods The investigators plan to randomize about 150 women undergoing primary and repeat cesarean deliveries to intra-abdominal chloroprocaine versus placebo prior to abdominal closure. Women will be excluded if they have ascertained or presumptive hypersensitivity to the ester type and major anesthetics; if they have chronic pelvic pain or if they refuse to participate in the study. The investigators' primary outcome measure will be postoperative pain as measured by visual analogue scale (VAS) at 1 hour after skin closure. Secondary outcomes will include objective pain as measured by VAS at 2, 6, 24 and 48 hours at rest and during mobilization, adverse effects of chloroprocaine (gastrointestinal side effects, pruritus), concomitant analgesic requirement, hospital readmissions and length of hospital stay. Analysis will follow the intention-to-treat principle. The investigators will also be studying the concentration/effect (PKPD) relationship of chloroprocaine use for pain control in the postpartum period. The time courses of the plasma concentrations of chloroprocaine will be analyzed with mixed effects pharmacokinetic-pharmacodynamic (PKPD).
NCT03414359 ↗ Comparison of Chloroprocaine vs Lidocaine for Epidural Anesthesia in Cesarean Delivery Completed University of Arkansas Early Phase 1 2018-02-15 Regional anesthesia is commonly used for elective and emergency cesarean delivery. It provides numerous safety advantages when compared to general anesthesia for both the mother and fetus1. Epidurals also have the added benefit of being able to provide pain relief throughout labor and in the event of cesarean delivery, epidural analgesia can be "extended" to provide surgical anesthesia. Numerous studies have been performed to assess the onset times of various local anesthetics when administered through an epidural catheter. Attempts to reduce anesthetic onset time and improve the quality of intraoperative analgesia have been attempted by using different local anesthetic solutions and by the addition of other drugs to the epidural solution (such as epinephrine, fentanyl and sodium bicarbonate).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nesacaine-mpf

Condition Name

Condition Name for Nesacaine-mpf
Intervention Trials
Surgical Anesthesia, Cesarean Section 1
Adverse Reaction to Spinal Anesthetic 1
Cerclage, Cervical 1
Cesarean Section 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nesacaine-mpf
Intervention Trials
Uterine Cervical Incompetence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nesacaine-mpf

Trials by Country

Trials by Country for Nesacaine-mpf
Location Trials
United States 5
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nesacaine-mpf
Location Trials
Arkansas 2
North Carolina 1
Oregon 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nesacaine-mpf

Clinical Trial Phase

Clinical Trial Phase for Nesacaine-mpf
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
N/A 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nesacaine-mpf
Clinical Trial Phase Trials
Completed 4
Withdrawn 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nesacaine-mpf

Sponsor Name

Sponsor Name for Nesacaine-mpf
Sponsor Trials
University of Arkansas 2
Oregon Health and Science University 1
Duke University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nesacaine-mpf
Sponsor Trials
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Colorcon
Baxter
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.